FDA Premarket Cybersecurity
Medical device cybersecurity for FDA premarket submissions: cyber-device scope, SBOMs, threat modeling and security testing, with practical podcast interviews.
Planning medical device cybersecurity before an FDA submission means understanding both the statutory requirements for cyber devices and FDA's recommendations for demonstrating safety and effectiveness. This page explains the distinction and connects you to interviews on secure development, SBOMs, threat modeling and testing. Use the official sources below for current requirements; podcast discussions are educational, not device-specific regulatory advice.
What FDA premarket cybersecurity actually requires
Section 524B of the Federal Food, Drug, and Cosmetic Act defines a cyber device using three conditions together: it includes software validated, installed or authorized by the sponsor as a device or in a device; it can connect to the internet; and it contains technological characteristics validated, installed or authorized by the sponsor that could be vulnerable to cybersecurity threats. Having software alone does not satisfy this definition. Evaluate the whole device system rather than assuming an offline label settles applicability.
For a cyber device in a covered premarket submission, section 524B requires a plan to monitor, identify and address postmarket vulnerabilities and exploits, including coordinated vulnerability disclosure; processes and procedures providing reasonable assurance that the device and related systems are cybersecure, with updates and patches; and an SBOM covering commercial, open-source and off-the-shelf software components. FDA's guidance separately recommends evidence such as threat modeling, cybersecurity risk assessment, architecture documentation, security testing and labeling. Guidance recommendations are not themselves legally binding requirements.
How to reduce avoidable submission gaps
Check the applicable submission pathway and FDA's current cybersecurity guidance before assembling evidence. For cyber devices, omitting information required by section 524B can affect whether FDA accepts the submission. A generic threat list or a vulnerability scan alone may not explain the device-specific risks, controls and testing results that reviewers need to evaluate.
Avoid treating cybersecurity as paperwork after design freeze. Early analysis can reveal architectural issues while there is still time to address them, document the controls, and test whether those controls work. It does not guarantee clearance or approval.
How strong teams approach it
Start cybersecurity alongside requirements definition. Build a threat model against the system architecture early, maintain security risk management as a distinct process that interfaces with safety risk management, generate an SBOM from the build pipeline, and schedule security testing early enough to remediate findings and retest. FDA distinguishes security risk management from safety risk management under ISO 14971; a single combined risk file is not a universal requirement.
They also write the submission for the reviewer. Each claimed control maps to a threat, each threat maps to test evidence, and the narrative explains the residual risk rationale in the language of patient harm. The episodes below feature engineers, regulatory leads, and consultants working through exactly these decisions on real programs.
Official FDA sources
- FDA medical-device cybersecurity: section 524B and submission questions
- Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
Reviewed November 1, 2026. Follow the FDA links for current guidance and applicability.
Cybersecurity questions, transcripts & guest biographiesMedical-device security glossaryPractical premarket questions
Based on FDA's February 3, 2026 final guidance and section 524B. Official requirements and recommendations are separate from the practical perspectives in our interviews.
Reviewed November 1, 2026 · Educational information, not device-specific regulatory advice.
Does my device fall under section 524B?
A cyber device must meet all three statutory conditions: sponsor-validated, installed or authorized software; the ability to connect to the internet; and sponsor-validated, installed or authorized technological characteristics that could be vulnerable to cybersecurity threats. FDA considers connectivity capability, including indirect connections—not just whether the device is online today. Devices outside this definition may still need cybersecurity evidence to support safety and effectiveness.
Practical next step: Document the device, companion software and connection paths before deciding applicability. Do not assume software alone qualifies a device or that an offline label excludes it.
FDA FAQs, Q2; guidance sections II and VII.BInterview perspective · 1:29 · What actually makes a medical device “cyber”?
The 7 Biggest Misconceptions About Medical Device Cybersecurity | Ep 86When should cybersecurity work start?
FDA recommends incorporating cybersecurity throughout development using a secure product development framework. Threat modeling, security risk management and security architecture are design activities, not just documents to assemble at the end. Security risk management is distinct from safety risk management, with the two processes informing each other.
Practical next step: Start with requirements and architecture, record threats and controls, and leave time to fix and retest findings before submission. Christian Espinosa discusses the costs of late-stage security work in Episode 89.
FDA guidance, sections V, V.A, V.A.1 and V.BInterview perspective · 2:08 · When cybersecurity should actually begin
When Should You Start Medical Device Cybersecurity? | Ep 89What should the submission include about software components?
For covered cyber-device submissions, section 524B requires an SBOM that includes commercial, open-source and off-the-shelf software components. FDA recommends machine-readable SBOMs consistent with NTIA minimum elements, plus component support status and end-of-support dates. Submissions should also identify known vulnerabilities, explain how they were discovered, and provide device- and system-specific safety and security risk assessments and applicable controls. These additional recommendations should not be confused with the statute's SBOM requirement.
Practical next step: Inventory the software actually shipped, identify versions and dependencies, and connect vulnerability assessments to the device's risks and mitigations—not just a generic component list.
FDA guidance, sections V.A.4(b) and VII.C.3Interview perspective · 2:00 · Why continuous SBOM monitoring matters
AI, Medical Devices and the Next Cybersecurity Arms Race with Liam Dowd | Ep 88Is a vulnerability scan enough for security testing?
A scan is one source of evidence, not a complete demonstration of security. FDA recommends multiple forms of cybersecurity testing, including testing security requirements, threat mitigations, vulnerabilities and penetration testing. The testing and its scope should relate to the device architecture and identified risks.
Practical next step: Document the tested system, tester independence and expertise, scope, duration, methods, results and mitigations, including rationales for unresolved or deferred findings; provide original third-party reports where applicable. Parker Daudt's Episode 87 interview explores how ethical hackers investigate attack paths and the impact of exploitation.
FDA guidance, section V.CInterview perspective · 10:26 · Vulnerability scanning versus penetration testing
How Ethical Hackers Find Weaknesses in Medical Devices with Parker Daudt | Ep 87What postmarket plans need to be ready before submission?
For covered cyber-device submissions, section 524B requires a plan to monitor, identify and address, as appropriate and in a reasonable time, postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures. It also requires designing, developing and maintaining processes and procedures to provide reasonable assurance that the device and related systems are cybersecure, and making updates and patches available to the device and related systems: for known unacceptable vulnerabilities on a reasonably justified regular cycle, and for critical vulnerabilities that could cause uncontrolled risks as soon as possible out of cycle.
Practical next step: Identify who receives reports, assesses risk, coordinates disclosure and validates and releases updates. Joe Saunders's interview adds a practical discussion of why patching alone is not a complete defense strategy; it does not replace FDA obligations.
FDA guidance, sections VII.C.1–2Interview perspective · 23:08 · The cost of constant patching and recertification
Building Cyber Resilience Into Medical Devices with Joe Saunders | Ep 85Host covering FDA Premarket
Need help with fda premarket for your medical device?
Blue Goat Cyber works with manufacturers on FDA premarket and postmarket cybersecurity. Schedule a free discovery session.
Schedule Discovery


